CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
selinexor (KPT-330)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02228525
NCT02228525Phase 2Completed
CompareCT.gov

A Phase II Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

Memorial Sloan Kettering Cancer Center·interventional·Posted Aug 29, 2014·Updated Mar 9, 2022

In Brief

A Phase 2 clinical trial evaluating selinexor (KPT-330) for Myelodysplastic Syndromes. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The purpose of this study is to see if selinexor will improve the blood counts and bone marrow function in people with your type of MDS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndromes
CountriesUnited States
CollaboratorsM.D. Anderson Cancer Center, Columbia University, Karyopharm Therapeutics Inc

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 29, 2014
Enrollment StartAug 27, 2014
Primary CompletionApr 6, 2021
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 11.8 years ago

Interventions

selinexor (KPT-330)drug